Effect of Ginkgo biloba extract on plasma steroid concentrations in healthy volunteers: A pilot study

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1337-1340

  Markowitz, John S ^a   DeVane, C Lindsay ^b   Lewis, John G ^c   Chavin, Kenneth D ^b   Wang, Jun Sheng ^b   Donovan, Jennifer L ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Androgens; EGb 761; Endogenous steroids; Ginkgo biloba; Supplement

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; CORTODOXONE; GINKGO BILOBA EXTRACT; HYDROCORTISONE; HYDROXYPROGESTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; PILOT STUDY; STEROID BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROSTENEDIONE; CROSS-OVER STUDIES; DEHYDROEPIANDROSTERONE SULFATE; DIHYDROTESTOSTERONE; FEMALE; GINKGO BILOBA; HUMANS; HYDROCORTISONE; MALE; PILOT PROJECTS; PLANT EXTRACTS; SEX HORMONE-BINDING GLOBULIN; STEROIDS; TESTOSTERONE;

EID: 26044458501     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1337     Document Type: Article

References (23)

1. Christen Y, Maixent JM. What is ginkgo biloba extract EGb 761? An overview: from molecular biology to clinical medicine. Cell Mol Biol 2002;48:601-11.
2. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004;64:465-72.
3. Chavez M, Chavez P. Ginkgo, II: clinical efficacy, dosage, and adverse effects. Hosp Pharm 1998;33:1076-95.
4. Diamond B, Shiflett S, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000;81:668-78.
5. McKenna D, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001;7:70-90.
6. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides. Endocrinology 1996;137:5707-18.
7. Trovero F, Brochet D, Tassin JP, Drieu K. Ginkgo biloba extract EGb761 reduces the development of amphetamine-induced behavioural sensitisation: effects on hippocampal type II corticosteroid receptors. Brain Res 1999;818:135-9.
8. Amri H, Drieu K, Papadopoulos V. Transcriptional suppression of the adrenal cortical peripheral-type benzodiazepine receptor gene and inhibition of steroid synthesis by ginkgolide B. Biochem Pharmacol 2003;65:717-29.
9. Auchus RJ, Miller WL. Molecular modeling of human p450c17 (17-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999;13:1169-S2.
10. Budzinski J, Foster B, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;74:273-82.
11. Zou L, Harkey M, Henderson G. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71:1579-89.
12. Gurley B, Gardner S, Hubbard M, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87.
13. Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003;23:576-81.
14. Yin OQ, Tomlinson B, Chow MS. Prediction and mechanism of herb-drug interaction: effect of ginkgo biloba on omeprazole in Chinese subjects (abstr). Clin Pharmacol Ther 2003;73:P94.
15. Shinozuka K, Umegaki K, Kubota Y, et al. Feeding of ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002;70:2783-92.
16. Elder PA, Lewis JG. An enzyme-linked immunosorbent assay (ELISA) for plasma testosterone. J Steroid Biochem 1985;22:635-8.
17. Lewis JG, Longley NJ, Elder PA. Monoclonal antibodies to human sex hormone-binding globulin (SHBG): characterization and use in a simple enzyme-linked immunosorbent assay (ELISA) of SHBG in plasma. Steroids 1999;64:259-65.
18. Vermeulen, A, Verdonck L, Kaufman, JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
19. Lewis JG, Bason LM, Elder PA. Production and characterization of monoclonal antibodies to dehydroepiandrosterone sulfate: application to direct enzyme-linked immunosorbent assays of dehydroepiandrosterone sulfate and androsterone/epiandrosterone sulfates in plasma. Steroids 1996;61:682-7.
20. Lewis JG, George PM, Elder PA. Plasma androsterone/epiandrosterone sulfates as markers of 5 alpha-reductase activity: effect of finasteride in normal men. Steroids 1997;62:632-5.
21. Lewis JG, Manley L, Whitlow JC, Elder PA. Production of a monoclonal antibody to cortisol: application to a direct enzyme-linked immunosorbent assay of plasma. Steroids 1992;57:82-5.
22. Lewis JG, Yeo KHJ, Elder PA. A competitive enzyme-linked immunosorbent assay for plasma 11-deoxycortisol (17,21 dihydroxy-4-pregnene-3,20-dione). Steroids 1986;47:365-72.
23. Yeo KHJ, Elder PA, Lewis, JG. An automated solid-phase 17α-hydroxyprogesterone ELISA method using a microtitre plate. Ann Clin Biochem 1998;25:293-7.